Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

August 4, 2017: By Jon Swedien
Mynosys Zepto disposable handpiece

Mynosys’ Zepto disposable handpiece

Mynosys has received a $1 million government grant to commercialize its Zepto capsulotomy system, the Fremont, California, company announced Aug. 1.

The National Eye Institute (NEI) of the National Institutes of Health (NIH) awarded Mynosys an SB1 Commercialization Readiness Program award, which is intended to support the transition of previously NIH-funded projects to the commercialization stage. Mynosys has received $5.3 million in total from the NIH’s Small Business Innovation Research program.

The Zepto, which received US 501(k) clearance in June, is designed to allow cataract surgeons to create automated, circular, exactly sized capsulotomies tailored to the individual patient.

The system is the first non-laser automated cataract capsulotomy device to gain US approval, but several others are expected to follow. The device received CE marking in December 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022